Q3 2024 Supernus Pharmaceuticals Inc Earnings Call Transcript
Key Points
- Supernus Pharmaceuticals Inc (SUPN) reported a 26% increase in total revenues for the third quarter of 2024, driven by strong performance from key growth products.
- The company achieved a significant 68% growth in net sales for its product KVIS, with prescriptions reaching an all-time quarterly high.
- Supernus Pharmaceuticals Inc (SUPN) raised its financial guidance for the full year 2024, expecting total revenues to range from $630 million to $650 million.
- The company reported a substantial increase in operating earnings, with a $32.8 million rise compared to the same quarter last year.
- Supernus Pharmaceuticals Inc (SUPN) has a strong balance sheet with approximately $403.2 million in cash and no debt, providing financial flexibility for potential M&A opportunities.
- Net sales for legacy products like Trendi Xr and Oxtellar Xr showed declines, with Trendi Xr down 26% from the same quarter last year.
- The first generic for Elex R entered the market, resulting in a 26% sequential decline in monthly prescriptions, indicating potential future erosion.
- The company expects further erosion in Trendi Xr sales for the remainder of 2024 and into 2025.
- Supernus Pharmaceuticals Inc (SUPN) faces potential competition from new non-stimulant entrants in the ADHD market, which could impact future sales.
- The company's pipeline products are still in early stages, with SPN 817 and SPN 820 in phase two trials, indicating a longer timeline before potential market entry.
Good afternoon and welcome to Separate Pharmaceutical third quarter person 24 financial results conference call. At this time, all participants are in listen-only mode later, we will conduct a question answer session, instructions will follow at that time. As a reminder, this conference call is being recorded. I would now like to turn the conference over to Peter Boso of IC R Health care, investor relations. Representative of Separate you may begin.
Thank you Marvin. Good afternoon, everyone. And thank you for joining us today for Supernus Pharmaceuticals third quarter, 2024 financial results conference call today. After the close of the market, the company issued a press release announcing these results on the call with me. Today are Sna's Chief Executive Officer, Jack Guitar and Chief Financial Officer Tim Deck.
Today's call is being made available via the investor relations section of the company's website at Ir dot superna dotcom. During the course of this call management may make certain forward
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
